ClinConnect ClinConnect Logo
Search / Trial NCT05223751

Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure

Launched by LANCASTER GENERAL HOSPITAL · Jan 25, 2022

Trial Information

Current as of July 22, 2025

Enrolling by invitation

Keywords

Heart Failure

ClinConnect Summary

To evaluate the effect of breathing training on the 6-minute walk test in a population of heart failure patients.

Enrollment/Baseline Visit During the enrollment visit, the participant will meet with the clinical research coordinator (CRC) to review any final questions regarding the study and the informed consent form will be signed. The enrollment visit must occur within one month of screening. Once the informed consent is signed, the following procedures will occur.

* Randomization: Participants will be randomized using REDCap in a 2:1 blocking method into the intervention group (breath...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. 18 years or older
  • 2. Signed informed consent
  • 3. NYHA class II-III heart failure
  • 4. EF ≤ 45% (echo within 1 year of enrollment)
  • 5. At least 30 days of stable medical regimen (no new neurohormonal blockade or Sodium-glucose co-transporter 2 inhibitors (SGLT2i). Dose adjustments allowed)
  • 6. Likely to be compliant with breath training as assessed by the provider
  • 7. Availability of a "smart" phone and internet access
  • 8. Established care at Lancaster General Health Penn Medicine
  • Exclusion Criteria:
  • 1. Cardiac resynchronization therapy (CRT) within 6 months
  • 2. Severe Chronic obstructive pulmonary disease (COPD)
  • 3. History of diaphragm paralysis
  • 4. Unable or unwilling to complete respiratory training protocol
  • 5. Decompensated or American College of Cardiology (ACC) Stage D Heart Failure (HF)
  • 6. Prior or planned chest/abdominal or nasal/facial surgery within 6 months
  • 7. Neuromuscular disease which impairs respiration
  • 8. Diagnosed cognitive impairment (unable to participate in training)
  • 9. Untreated obstructive severe sleep apnea (AHI \> 30)
  • 10. Severe valvular heart disease
  • 11. Uncontrolled atrial fibrillation (Ave Heart Rate (HR) \> 100 bpm)
  • 12. Orthopedic or other limitations which impair the 6-minute walk test

About Lancaster General Hospital

Lancaster General Hospital (LGH) is a leading healthcare institution dedicated to providing exceptional patient care, advancing medical research, and fostering education in the healthcare field. As a prominent clinical trial sponsor, LGH is committed to exploring innovative treatments and improving health outcomes through rigorous research methodologies. With a focus on collaboration and community engagement, LGH leverages its extensive resources and expertise to contribute to the advancement of medical science, ensuring that patients have access to cutting-edge therapies and interventions. The hospital's commitment to excellence is reflected in its state-of-the-art facilities and a multidisciplinary team of healthcare professionals dedicated to enhancing the quality of life for individuals and communities.

Locations

Lancaster, Pennsylvania, United States

Patients applied

0 patients applied

Trial Officials

Roy Small, MD

Principal Investigator

Medical Director

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials